T-Therapeutics
Biotech / TCR bispecific immunotherapies, Cambridge
Develops first-in-class TCR bispecific immunotherapies from its T-cell receptor discovery platform. It raised £24m in its Series A in November 2025. We can't read its job board yet.
Backed by BGF, Cambridge Innovation Capital, Sofinnova Partners and Tencent. Total raised $91M (Series A total).
On the Home Office register of licensed visa sponsors.
Open roles over time
We can't read this company's job board yet.
Hiring momentum
Roles per weekNot tracked yet.
In the news
- FundingBusiness Weekly, 12 Nov 2025Tencent backs new raise that takes T-Therapeutics Series A to $91m